View Older Stories View More Recent Stories
-
Lexaria Bioscience Releases Second Episode of Investor Video Series
-
Lexaria advances human study testing oral semaglutide formulations
-
Lexaria Updates Progress on Human Study #7
-
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
-
Lexaria extends pharmaceutical partnership through december 2026
-
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
-
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
-
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
-
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
-
Lexaria notes FDA approval of Eli Lilly's oral weight-loss drug Foundayo
-
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
-
Lexaria signs contracts for human study of oral semaglutide formulation
-
Lexaria to Begin New Human Clinical Study in GLP-1
-
Lexaria receives 5 new patents including diabetes and hypertension treatments
-
Lexaria's Robust Patent Portfolio Continues to Grow
-
Lexaria in talks with pharma companies for oral GLP-1 drug development
-
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
-
Lexaria Bioscience plans three studies for drug delivery research
-
Lexaria Announces New R&D Plans for 2026
-
Lexaria Announces Positive Final Results From Human Pilot Study #5
-
Lexaria receives six new patents, bringing total to 60 worldwide
-
Lexaria Awarded Six Additional Patents
-
Lexaria Bioscience CEO outlines 2025 progress and 2026 plans
-
Lexaria Releases Annual Letter from the CEO
-
Lexaria reports additional Phase 1b study results for drug delivery platform
-
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
-
Lexaria Bioscience (LEXX) files for 2.75M share offering by selling stockholders
-
Lexaria Bioscience (LEXX) PT Lowered to $1.50 at H.C. Wainwright
-
Lexaria achieves primary endpoint in Phase 1b GLP-1 study
-
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
-
Lexaria Bioscience closes $3.5 million registered direct offering
-
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Lexaria Bioscience raises $3.5 million in registered direct offering
-
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Lexaria Bioscience (LEXX) files for 2.76M share offering by selling stockholders
-
Lexaria extends pharmaceutical partnership agreement through April 2026
-
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
-
Lexaria Bioscience hires advisory firm, receives 4 new patents
-
Lexaria Bioscience Corp. Provides Strategic Update
-
Lexaria Bioscience closes $4 million registered direct offering
-
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Lexaria Bioscience raises $4 million in registered direct offering
-
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Lexaria reports enhanced brain delivery of semaglutide using DehydraTECH
-
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
-
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
-
Lexaria completes patient dosing in Phase 1b GLP-1 study
-
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
-
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
-
Lexaria Bioscience (LEXX) PT Lowered to $4 at H.C. Wainwright
